Alpha Cognition Inc. (NASDAQ:ACOG) Stock Has Consensus Target Price of $18.00

Shares of Alpha Cognition Inc. (NASDAQ:ACOG) have been given a consensus recommendation of “Buy” by the five analysts that are presently covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a buy rating. The average 12 month price target among brokers that have issued a report on the stock in the last year is $18.00.

A number of analysts have commented on ACOG shares. Wall Street Zen raised Alpha Cognition from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Craig Hallum restated a “buy” rating and issued a $17.00 price objective on shares of Alpha Cognition in a research note on Friday, August 14th. B. Riley Financial began coverage on Alpha Cognition in a research report on Thursday, August 20th. They issued a “buy” rating and a $21.00 target price on the stock. Raymond James Financial started coverage on Alpha Cognition in a research note on Friday, July 10th. They set an “outperform” rating and a $20.00 price objective for the company. Finally, HC Wainwright increased their price target on shares of Alpha Cognition from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Monday, August 17th.

Insider Activity at Alpha Cognition

In other Alpha Cognition news, Director Robert Wills bought 10,000 shares of the stock in a transaction on Friday, August 21st. The shares were bought at an average price of $9.62 per share, with a total value of $96,200.00. Following the purchase, the director directly owned 32,241 shares in the company, valued at $310,158.42. This trade represents a 44.96% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 8.60% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ACOG. ACT Capital Management LLC acquired a new position in Alpha Cognition in the fourth quarter valued at about $335,000. Aristides Capital LLC grew its stake in shares of Alpha Cognition by 1.4% in the first quarter. Aristides Capital LLC now owns 218,510 shares of the company’s stock valued at $1,200,000 after buying an additional 3,052 shares in the last quarter. AWM Investment Company Inc. purchased a new stake in shares of Alpha Cognition in the 2nd quarter valued at $12,073,000. Finally, Opaleye Management Inc. raised its holdings in shares of Alpha Cognition by 13.0% in the 2nd quarter. Opaleye Management Inc. now owns 2,895,467 shares of the company’s stock valued at $20,905,000 after buying an additional 333,517 shares during the period.

Alpha Cognition Stock Performance

NASDAQ ACOG opened at $9.04 on Thursday. The company has a market capitalization of $196.89 million, a P/E ratio of -8.22 and a beta of 2.32. Alpha Cognition has a one year low of $4.50 and a one year high of $10.14. The stock has a 50 day moving average price of $9.01 and a 200-day moving average price of $7.50.

Alpha Cognition (NASDAQ:ACOG) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.01). The business had revenue of $6.00 million during the quarter, compared to the consensus estimate of $4.38 million. Alpha Cognition had a negative net margin of 153.61% and a negative return on equity of 54.60%. As a group, equities analysts predict that Alpha Cognition will post -1.38 EPS for the current fiscal year.

About Alpha Cognition

Alpha Cognition Inc (NASDAQ: ACOG) is a biopharmaceutical company focused on developing and commercializing treatments for neurodegenerative disorders, including Alzheimer’s disease and related cognitive conditions. The company’s work is centered on addressing unmet needs in the diagnosis, management and treatment of diseases that affect memory and cognitive function.

Its lead commercial product is ZUNOVO (memantine hydrochloride extended-release capsules), a prescription therapy approved by the U.S.